🔗 Share this article

As the US undertakes unprecedented changes to its vaccination guidelines, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about Covid vaccinations throughout the pandemic and has zeroed in on possible deaths following Covid vaccination in her brief tenure at the FDA.

Planned Shifts to Childhood Immunization Schedule

Health officials planned to announce sweeping changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US out of step with much of the world with little proof for public health gain. This reveal has been pushed back until the next year.

Instead of the top vaccines chief, Høeg is scheduled to present at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting certain pediatric shot schedules in the US to become more like Denmark's approach, a society with comprehensive healthcare and a population approximately the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has no apparent experience in drug development, approval processes or management, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a clinical trial. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”

Past commissioners of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she lacks the type of experience that former directors who led the center have had.”

The drug center has an immense portfolio at the agency, she stated.

“The public just zeroes in on the new drug program, but the generic program authorizes numerous generic drugs. There is also a biosimilars program, non-prescription drug unit and other areas, and all of those have to be managed,” she said. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the position, which supervises in excess of 5,000 personnel. “It’s a huge management job, if you do it right,” Woodcock added.

Agency Reaction and Disputed Programs

When asked about questions about Dr. Høeg's qualifications and whether this selection represents more teamwork among regulatory chiefs on vaccines, a press secretary responded that the “inquiries are based on incorrect premises”.

“This background matches the functions of her position,” the official explained, citing the period Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a disputed rapid therapy clearance system that allegedly troubled her preceding directors. “By what process are these medications being selected for this voucher program? Who is making the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he said, “the FDA appears to be shifting towards more relaxed oversight of most medications, with the exception of immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, past, Howard have noted. She released a study using unconfirmed volunteer-provided data to estimate the frequency of myocarditis following COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the current administration encompassed changing rules for novel immunizations and discontinuing “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has reportedly suggested preventing adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who commences with her beliefs and reverse-engineers to retrofit the evidence in a very deceptive, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other skeptics, {like|